Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-025-07528-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Huan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Lupus Nephritis, Autoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Project of China, Jiangsu Biobank of Clinical Resources.
Abstract (Originalsprache)
OBJECTIVE: To explore the associations of novel serum autoantibodies with disease activity and organ injuries in patients with lupus nephritis (LN). METHOD: This study included 75 patients with active LN (5 class II, 37 class IV, and 33 class V). Indirect immunofluorescence was used to measure serum anti-dsDNA; ELISA was used to measure serum anti-PLA2R and anti-C1q, and the Luminex method was used to measure 58 novel serum autoantibodies, with a median fluorescence intensity (MFI)/threshold ≥ 1.5 as the antibody positivity cutoff. RESULTS: The positivity rates for 11 novel antibodies (anti-PLA2R, anti-P2RY11, anti-DEXI, anti-HARS, anti-TUBA1B, anti-KRT8, anti-TUBB, anti-NCL, anti-HSPB1, anti-AGRN, and anti-LGALS8) were highly associated with SLE activity and were inconsistent with those for anti-dsDNA and anti-C1q. Anti-TUBA1B and anti-AGRN positivity may independently influence LN with extrarenal organ involvement (OR = 6.73, 95% CI = 1.19 ~ 38.09; OR = 6.11, 95% CI = 1.32 ~ 28.25, respectively). The positivity rate for anti-PLA2R as detected by the Luminex platform was 40%, whereas the rate among those detected by ELISA was 12.7%. Twenty-one patients who achieved renal remission were retested, and the positivity rates of anti-PLA2R (42.9% vs. 9.5%, P = 0.014), anti-KRT8 (47.6% vs. 4.8%, P = 0.001), and anti-AGRN (38.1% vs. 4.8%, P = 0.008) also significantly decreased from baseline. CONCLUSION: On the basis of Luminex technology, the present study revealed multiple novel autoantibodies related to SLE activity and organ injury, especially anti-PLA2R, anti-KRT8, and anti-AGRN, thereby providing novel serological markers for the assessment of activity in patients with LN. Anti-TUBA1B and anti-AGRN are strongly associated with extrarenal involvement. Key Points • The Luminex method is highly sensitive and high-throughput for detecting serum autoantibodies. • LN patients with anti-TUBA1B and anti-AGRN positivity are more likely to be complicated by extrarenal organ involvement. • Serum anti-PLA2R, anti-KRT8, and anti-AGRN reflect the activity of SLE and provide novel serological markers for the evaluation of LN patients negative for anti-dsDNA and anti-C1q.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. huwx0202@nju.edu.cn.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Project of China
- Jiangsu Biobank of Clinical Resources
Zitieren
APA
Zhang, H., Deng, J., Liu, Y., Xia, W., Zhuang, L., Zhou, H., Liu, Z., Zhang, H., & Hu, W. (2025). Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07528-3
Vancouver
Zhang H, Deng J, Liu Y, Xia W, Zhuang L, Zhou H, et al. Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07528-3
BibTeX
@article{Zhang2025,
author = {Zhang, Huan and Deng, Jiayi and Liu, Yang and Xia, Wen and Zhuang, Lulu and Zhou, Houan and Liu, Zhengzhao and Zhang, Haitao and Hu, Weixin},
title = {Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-025-07528-3}
}
EUVIMED